Despite a slowing in deal making due to economic uncertainty and deal friction caused by the global pandemic in H1, the biopharmaceutical industry has rebounded nicely in H2 with large increases in both deal volume and deal value. Not surprisingly, growth was driven by a focus on COVID-19 assets as well as mergers and acquisitions within the usual drivers of oncology and immunology therapeutic areas. We expect oncology, immunology, and cell therapy to remain as in-demand areas for deal-makers in 2021. Additionally, the influx of funding into the biopharma industry continues to drive an upward trend of US IPOs with 42 companies going public in H2 2020.
Download the latest report on the biopharma dealmaking landscape below.
